Angle PLC announces potential in screening immunotherapy treatments


  • Parsortix isolation of CTCs highlights the relationship between PD-L1 expression and epithelial-to-mesenchymal transition (EMT)
  • CTCs in the process of epithelial mesenchymal transition (EMTing CTC) were found to be most closely associated with PD-L1 expression

GUILDFORD, SURREY/ACCESSWIRE/January 21, 2022/ANGLE plc (OTCQX:ANPCY)(AIM:AGL), a world leader in liquid biopsy, is pleased to announce that Edith Cowan University, Perth, Australia, has published the results of a study in patients with ovarian cancer using Parsortix® system. The main objective of this study was to demonstrate the ability to assess the expression of epithelial and mesenchymal markers, as well as the PD-L1 status, of circulating tumor cells (CTCs) isolated using the Parsortix system, which can help predict whether patients will respond to immunotherapy drugs.

The Parsortix system was selected by the researchers for the study because of its unbiased CTC enrichment capability, allowing for the isolation of epithelial, mesenchymal and transitional cancer cells (EMTing-CTC). This is clinically relevant because, although transition to a mesenchymal phenotype is associated with increased metastatic potential and worse prognosis, many methods of CTC isolation, including the major antibody-based system, capture only epithelial cells and lack mesenchymal and EMTing cells.

Blood from 16 patients with ovarian cancer was collected and processed using the Parsortix system. The isolated CTCs were stained with several markers to determine their phenotype (epithelial, EMTing or mesenchymal) and their PD-L1 status. CTCs were identified in 63% of patients, and of these CTCs, 61% were exclusively epithelial, 26% exclusively mesenchymal, and 11% were positive for epithelial and mesenchymal markers (EMTing-CTC). The remaining 2% expressed only the ovary-specific marker. Half of the patients with detectable CTCs were PD-L1 positive. PD-L1-positive CTCs were more common among EMTing CTCs, accounting for 76% of observed EMTing CTCs, with a significant association between the two compared to epithelial and mesenchymal CTCs.

This study highlights the potential of this multi-marker staining procedure to be useful in the investigation of PD-L1 status, evaluating its usefulness as a biomarker to select patients for inclusion in clinical trials who may better respond to clinical trials. immunotherapy treatments. Currently, the proportion of patients who respond to PD-L1 or PD-1 inhibitors is low, at around 13% to 50%, indicating a clear need to improve patient selection because non-responders do not benefit from the treatment but are at risk of developing hyper-progressiveness. disease and drug toxicity with adverse events related to the immune system.

ANGLE Founder and Managing Director Andrew Newland commented:
“We are pleased to report on these promising pilot data demonstrating the utility of the Parsortix system for the unbiased isolation of multiple CTC subsets in patients with ovarian cancer. While ctDNA is increasingly used for stratification of female cancer patients, it is unable to provide information in PD-L1 status. In contrast, CTCs can provide PD-L1 status. ANGLE is currently in the process of validating a PD-L1 test in its clinical laboratories as a key part of its pharmaceutical services offering for clinical trials.

The research has been published as a peer-reviewed publication in the Journal Cancer and is available online at

For more information:


+44 (0) 1483 343434

Andrew Newland, Managing Director
Ian Griffiths, Chief Financial Officer
Andrew Holder, Head of Investor Relations

Berenberg (NOMAD and co-broker)
Toby Flaux, Jen Clarke, Milo Bonser, Shiv Dave

+44 (0) 20 3207 7800

Jefferies (Joint Broker)
Max Jones, Thomas Bective

+44 (0) 20 7029 8000

FTI Council
Simon Conway, Ciara Martin
Matthew Ventimiglia (USA)

+44 (0) 203 727 1000
+1 (212) 850 5624

For frequently used terms, please see the Company’s website at

Notes for Editors

About ANGLE plc

ANGLE is one of the world leaders in liquid biopsy with sample-response solutions. ANGLE’s proven, patented platforms include circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost-effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE’s cell separation technology is called Parsortix® system, and it allows the use of a liquid biopsy (a simple blood test) to deliver the cells of interest to the user in a format suitable for several types of downstream analysis. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all CTC types as well as CTC clusters in a viable (live) form. CTCs provide a complete picture of a cancer; as an intact cell, they allow DNA, RNA and protein analysis and can provide analysis comparable to a tissue biopsy. As CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer grows and changes over time and there is a clear medical need for up-to-date information about a patient’s tumor status. Additionally, live CTCs harvested by the Parsortix system can be cultured, providing the opportunity to test tumor response to drugs outside of the patient.

Parsortix technology is covered by 26 issued patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three broad patent families in development worldwide.

The Parsortix system has CE marking in Europe for the indicated use and in the United States a De Novo submission has been made to the FDA for Parsortix® The PC1 system is seeking FDA clearance with a Class II classification for use with patients with metastatic breast cancer. FDA clearance is considered the global standard. ANGLE seeks to be the first-ever FDA-cleared system for harvesting CTCs for further analysis.

ANGLE has also completed two separate clinical studies of 200 subjects as part of a program designed to develop a pelvic mass triage test for ovarian cancer, with results showing best-in-class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage test has been refined and optimized and a clinical verification study of 200 patients has now completed recruitment.

ANGLE’s technology for multiplex evaluation of proteins and nucleic acids of all types is called HyCEADMT platform and is based on patented flow-through-matrix technology. It enables low cost, highly multiplexed, fast and sensitive capture of targets from a wide variety of sample types. A proprietary chemical approach (the HyCEAD method) allows the capture and amplification of more than 100 biomarkers simultaneously in a single reaction. The HyCEAD system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and has been used in the Ovarian Cancer Pelvic Mass Triage test to achieve the best accuracy of its category (AUC-ROC) of 95.1%.

ANGLE’s proprietary technologies can be combined to deliver automated, sample-to-response results in centralized lab and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centers and leading companies such as Abbott, Philips and QIAGEN, and works closely with key CTC translational research clients. These Key Opinion Leaders (KOLs) strive to identify applications with medical utility (clear patient benefit) and obtain clinical data that demonstrates this utility in patient studies. The body of evidence for the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer, as well as KOLs with 55 peer-reviewed publications and numerous accessible posters. to the public, available on our website.

ANGLE has established clinical services laboratories in the UK and US to accelerate the commercialization of the Parsortix system and act as demonstrators to support product development. The labs provide services to pharmaceutical and biotech customers for the use of Parsortix in cancer drug trials and, once the labs are accredited and the assays validated, will provide laboratory-developed tests (LDTs) for patient management.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, which is part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For more information, please contact [email protected] or visit


See the source version on

Martin E. Berry